Join BioVie Inc. for a virtual key opinion leader (KOL) event featuring Suzanne de la Monte, MD, MPH (Brown University Warren Alpert Medical School, Providence VA Medical Center), who will join company management to discuss how bezisterim’s mechanism of action addresses the pathology and progression of neurodegenerative disease, including Parkinson’s disease.

The event will provide an update on BioVie’s Phase 2 trial evaluating bezisterim (NE3107) for the treatment of Parkinson’s disease. Bezisterim is a novel, orally-administered small molecule that has shown to reverse insulin resistance and selectively inhibit inflammation-driven ERK- and NF-κB-stimulated inflammatory mediators without inhibiting their homeostatic functions. Inflammation and the associated insulin resistance are required to create Parkinson’s symptoms.

A live question and answer session will follow the formal presentations.